FindTrial
Sign In

Estimation of Dynamics of Humoral and Cellular Immunity in COVID-19 Patients

Estimation of Dynamics of Humoral and Cellular Immunity in COVID-19 Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04649840
Enrollment
274
Registered
2020-12-02
Start date
2020-10-01
Completion date
2021-12-09
Last updated
2021-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

COVID-19

Brief summary

The goal of the project: to study the dynamics of the humoral and cellular immunity in patients after pneumonia caused by the SARS-CoV-2 virus at different time intervals, in order to predict the duration of immune protection

Detailed description

* to form study groups of patients (at least 60 patients in total) who have recovered from pneumonia of varying severity caused by the SARS-CoV-2 virus (at least 30 patients in each of the groups of patients who have had pneumonia in moderate and severe forms); * to investigate the parameters of cellular immunity (the content of antigen-specific T-cells to the main viral antigens - proteins S, N, M) in patients of different groups included in the trials, in dynamics 3, 6, 9 and 12 months after the COVID-19-associated pneumonia; * to investigate the indicators of humoral immunity (the content of IgG to the main viral antigens - proteins S, N, M) in patients of different groups included in the trials, in dynamics 3, 6, 9 and 12 months after the COVID-19-associated pneumonia.

Interventions

DIAGNOSTIC_TESTHumoral and cellular immunity

Humoral (IgG) and cellular (antigen-specific cells) immunity

Sponsors

Belarusian State Medical University
CollaboratorOTHER
The Republican Research and Practical Center for Epidemiology and Microbiology
CollaboratorOTHER
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Lead SponsorOTHER_GOV

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients recovered from the COVID-19 associated pneumonia (moderate and severe) in 1-3 month interval before inclusion into the trial;

Exclusion criteria

* cancer; * drug and alcohol addiction; * autoimmune diseases.

Design outcomes

Primary

MeasureTime frameDescription
The dynamics of humoral and cellular immunity1 yearThe dynamics of both humoral and cellular immunity in response to COVID-19 infection

Countries

Belarus

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026